Reference
[1] Brodsky R A. How I Treat Paroxysmal Nocturnal
Hemoglobinuria[J]. Blood, 2021, 137(10): 1304–1309. DOI:
10.1182/blood.2019003812
[2] Devalet B, Mullier F, Chatelain B, et al. Pathophysiology,
diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a
review[J]. European Journal of Haematology, 2015, 95(3): 190–198.
DOI: 10.1111/ejh.12543
[3] Huang C, Wang Y, Li X, et al. Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet
(London, England), 2020, 395(10223): 497–506. DOI:
10.1016/S0140-6736(20)30183-5
[4] Aleem A, Akbar Samad A B, Slenker A K. Emerging Variants of
SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)
[A]. In: StatPearls[M]. Treasure Island (FL): StatPearls
Publishing, 2022.
[5] Afzali B, Noris M, Lambrecht B N, et al. The state of complement
in COVID-19[J]. Nature Reviews. Immunology, 2022, 22(2): 77–84.
DOI:
10.1038/s41577-021-00665-1
[6] Noris M, Benigni A, Remuzzi G. The case of complement activation
in COVID-19 multiorgan impact[J]. Kidney International, 2020, 98(2):
314–322. DOI:
10.1016/j.kint.2020.05.013
[7] A H, N H, J B. COVID-19 infection presenting as paroxysmal
nocturnal hemoglobinuria[J]. Clinical case reports, Clin Case Rep,
2021, 9(8). DOI:
10.1002/ccr3.4636
[8] A G, T C, P B, et al. Severe COVID-19 infection in a patient
with paroxysmal nocturnal hemoglobinuria on eculizumab therapy[J].
Leukemia & lymphoma, Leuk Lymphoma, 2021, 62(6). DOI:
10.1080/10428194.2020.1869963
[9] Sokol J, Nehaj F, Mokan M, et al. COVID19 infection in a patient
with paroxysmal nocturnal hemoglobinuria[J]. Medicine, 2021,
100(20): e25456. DOI:
10.1097/MD.0000000000025456
[10] Shikdar S, Borogovac A, Mohamad E, et al. COVID19 infection in
a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria
(PNH) with Ravulizumab[J]. Thrombosis Journal, 2021, 19: 75. DOI:
10.1186/s12959-021-00330-6
[11] Araten D J, Belmont H M, Schaefer-Cutillo J, et al. Mild
Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic
Monoclonal Antibodies Targeting C5 Complement for Hematologic
Disorders[J]. The American Journal of Case Reports, 2020, 21:
e927418-1-e927418-4. DOI:
10.12659/AJCR.927418
[12] Pike A, Muus P, Munir T, et al. COVID‐19 infection in patients
on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal
Haemoglobinuria service experience[J]. British Journal of
Haematology, 2020, 191(1): e1–e4. DOI:
10.1111/bjh.17097
[13] Barcellini W, Fattizzo B, Giannotta J A, et al. COVID‐19 in
patients with paroxysmal nocturnal haemoglobinuria: an Italian
multicentre survey[J]. British Journal of Haematology, 2021, 194(5):
854–856. DOI:
10.1111/bjh.17558
[14] Kulasekararaj A G, Lazana I, Large J, et al. Terminal
complement inhibition dampens the inflammation during COVID‐19[J].
British Journal of Haematology, 2020, 190(3): e141–e143. DOI:
10.1111/bjh.16916
[15] Schüller H, Klein F, Lübbert M, et al. Hemolytic crisis in a
patient treated with eculizumab for paroxysmal nocturnal hemoglobinuria
possibly triggered by SARS-CoV-2 (COVID-19): a case report[J].
Annals of Hematology, 2021, 100(3): 841–842. DOI:
10.1007/s00277-020-04318-6
[16] Pravdic Z, Mitrovic M, Bogdanovic A, et al. COVID-19 Presented
with Deep Vein Thrombosis in a Patient with Paroxysmal Nocturnal
Haemoglobinuria[J]. Hämostaseologie, Georg Thieme Verlag KG, 2021,
41(5): 397–399. DOI:
10.1055/a-1554-6432
[17] Iannuzzi A, Parrella A, De Ritis F, et al. Pancytopenia in a
Case of Aplastic Anaemia/Paroxysmal Nocturnal Haemoglobinuria Unmasked
by SARS-CoV-2 Infection: A Case Report[J]. Medicina, 2022, 58(9):
1282. DOI:
10.3390/medicina58091282
[18] Barcellini W, Fattizzo B, Quattrocchi L, et al; COVID-19
Infection in Patients with Paroxysmal Nocturnal Hemoglobinuria in Italy.
Blood 2020; 136 (Supplement 1): 36–37. DOI:
https://doi.org/10.1182/blood-2020-138721
[19] Schrezenmeier H, Röth A, Araten D J, et al. Baseline clinical
characteristics and disease burden in patients with paroxysmal nocturnal
hemoglobinuria (PNH): updated analysis from the International PNH
Registry[J]. Annals of Hematology, 2020, 99(7): 1505–1514. DOI:
10.1007/s00277-020-04052-z
[20] Moore J B, June C H. Cytokine release syndrome in severe
COVID-19[J]. Science, American Association for the Advancement of
Science, 2020, 368(6490): 473–474. DOI: 10.1126/science.abb8925
[21] Passoni R, Lordani T V A, Peres L A B, et al. Occurrence of
acute kidney injury in adult patients hospitalized with COVID-19: A
systematic review and meta-analysis[J]. Nefrologia, 2022, 42(4):
404–414. DOI:
10.1016/j.nefroe.2022.11.005
[22] Clark D A, Butler S A, Braren V, et al. The kidneys in
paroxysmal nocturnal hemoglobinuria[J]. Blood, 1981, 57(1): 83–89.
DOI: 10.1182/blood.V57.1.83.83
[23] Risitano A M, Peffault de Latour R. How we(’ll) treat
paroxysmal nocturnal haemoglobinuria: diving into the future[J].
British Journal of Haematology, 2022, 196(2): 288–303. DOI:
10.1111/bjh.17753
[24] Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the
complement inhibitor eculizumab on kidney function in patients with
paroxysmal nocturnal hemoglobinuria[J]. American Journal of
Hematology, 2010, 85(8): 553–559. DOI:
10.1002/ajh.21757
[25] Brodsky R A, Young N S, Antonioli E, et al. Multicenter phase 3
study of the complement inhibitor eculizumab for the treatment of
patients with paroxysmal nocturnal hemoglobinuria[J]. Blood, 2008,
111(4): 1840–1847. DOI:
10.1182/blood-2007-06-094136
[26] Hillmen P, Muus P, Röth A, et al. Long‐term safety and efficacy
of sustained eculizumab treatment in patients with paroxysmal nocturnal
haemoglobinuria - Hillmen - 2013 - British Journal of Haematology -
Wiley Online Library[J]. British Journal of Haematology, 2013,
162(1): 62–73. DOI:
10.1111/bjh.12347
[27] Hillmen P, Hall C, Marsh J C W, et al. Effect of Eculizumab on
Hemolysis and Transfusion Requirements in Patients with Paroxysmal
Nocturnal Hemoglobinuria[J]. New England Journal of Medicine,
Massachusetts Medical Society, 2004, 350(6): 552–559. DOI:
10.1056/NEJMoa031688
[28] Di Franco S, Alfieri A, Petrou S, et al. Current status of
COVID-19 treatment: An opinion review[J]. World Journal of Virology,
2020, 9(3): 27–37. DOI:
10.5501/wjv.v9.i3.27
[29] Wang R, Xiao H, Guo R, et al. The role of C5a in acute lung
injury induced by highly pathogenic viral infections[J]. Emerging
Microbes & Infections, 2015, 4(5): e28. DOI:
10.1038/emi.2015.28
[30] Annane D, Heming N, Grimaldi-Bensouda L, et al. Eculizumab as
an emergency treatment for adult patients with severe COVID-19 in the
intensive care unit: A proof-of-concept study[J]. EClinicalMedicine,
2020, 28: 100590. DOI:
10.1016/j.eclinm.2020.100590
[31] F D, Fg N, G P, et al. Eculizumab treatment in patients with
COVID-19: preliminary results from real life ASL Napoli 2 Nord
experience[J]. European review for medical and pharmacological
sciences, Eur Rev Med Pharmacol Sci, 2020, 24(7). DOI:
10.26355/eurrev_202004_20875